Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» SCR's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Traded in other countries:VV5.Germany,

Simcere Pharmaceutical Group was incorporated in the Cayman Islands as a listing vehicle on August 4, 2006. The Company is mainly engaged in the research, development, manufacture and distribution of pharmaceutical products in the People's Republic of China (the 'PRC'). The Company focuses its strategy on the development of first-to-market generic and innovative pharmaceuticals, and have introduced a first-to-market generic anti-stroke medication under the brand name Bicun, a 5-FU sustained release implant under the brand name Sinofuan, and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 45 main pharmaceutical products and the distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under the Company's brand names. As of March 31, 2009, the Company also had 12 product candidates in stages of development, including treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, nausea and vomiting associated with chemotherapy. The Company's main products are Antibacterial and Antiviral - Amoxicillin granules, capsules and tablets; Amoxicillin with clavulanate potassium granules, tablets and injection; biapenem injection; cefaclor dry suspension; azithromycin granules and ribavirin dispersible tablets; Anti-cancer - Recombinant human endostatin injection, nedaplatin injection, lentinan injection and fluorouracil implants. Anti-Allergic - Clemastine fumarate capsules and clemastine fumarate dry suspension; Anti-Osteoporosis - Alfacalcidol soft capsules Cardiovascular and Cerebrovascular - Edaravone injection; amlodipine maleate tablets and sumatriptan succinate tablets; Digestive Conditions - Smectite powder and aldioxa tablets; Non-Steroidal Anti-Inflammatory - Diclofenac sodium sustained-release capsules and gelatin; Respiratory System - Herbal medicine used for the treatment of cough in liquids and tablets; artificial cowbezoar and chlorphenamine maleate granules compound paracetamol and amantadine hydrochloride tablets; compound zinc gluconate; pediatric paracetamol; Urinary Conditions - Naftopidil tablets and herbal oral solutions. The main raw materials used for its products are the necessary active ingredients of its pharmaceuticals. The Company's source such raw materials, as well as packaging materials, from different independent suppliers in China. The Company's marketing and distribution activities are mainly carried out by its subsidiaries, Jiangsu Simcere and Shanghai Simcere. It sells all of the Company's products to pharmaceutical distributors in China. The Company relies mainly on a combination of patent, trademark and trade secret protections, as well as employee and third party confidentiality agreements to safeguard its intellectual property. The Company's operations and facilities are subject to environmental laws and regulations stipulated by the national and the local environment protect



Valuation & Return


More Statistics

Revenue (TTM) (Mil) $332.0
EPS (TTM) $ 1.27
Short Percentage of Float0.00%

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)